What is mAb?

COVID-19 monoclonal antibodies (mAb) are treatments available to people who have tested positive for COVID-19, exhibit mild to moderate symptoms of the disease, and who are at high risk of developing severe COVID-19. When given in the first few days of illness, treatments can prevent hospitalizations and/or severe complications caused by COVID-19.



We Need You

Our research team is currently conducting telephone surveys of patients who may have tested positive for COVID-19, and experienced symptoms where you would complete telephone surveys at 2 weeks, 4 weeks, and 3 months from the date you diagnosed with COVID-19.

Go to the Participate in mAb Research page, click on "Request to take the survey" under the community members section. 


mAb Colorado in the News

NBC News -

Treating COVID-19 early with monoclonal antibodies, reduces your risk of hospitalization and death by up to 85%. Check out this NBC News story, featuring Dr. Anthony Fauci and UCHealth's Dr. Adit Ginde & Dr. Marion Sills. Watch now.


Denver Post -


Read this Denver Post story about monoclonal antibody treatment from mAb Colorado's own Dr. Adit Ginde from UCHealth & Dr. Lindsey Fish from Denver Health. Read now.



Colorado COVID-19 Alert!

The Colorado Department of Public Health & Environment (CDPHE) has issued an urgent advisory regarding the increasing spread of the COVID-19 Delta variant in Colorado.

According to CDPHE, since the first case of the variant in Colorado was identified in early May, it has spread to more than 24 counties throughout the state.

Public health experts say that the Delta variant poses a great risk of future large outbreaks unless we take action now. All health care providers are asked to:

  • Encourage vaccination for all those who are eligible.
  • Inform their communities of the availability and efficacy of monoclonal antibody (mAb) treatments for those who are diagnosed with COVID-19 in order to avoid hospitalization.

Key updates as of June 18, 2021: 

  • The SARS-CoV-2 B.1.617.2 (Delta) variant has been rapidly increasing in prevalence in Colorado since it was first identified in the state on May 5, 2021. On June 14, the CDC classified the Delta variant as a variant of concern.
  • Updated surveillance information can be found at: https://covid19.colorado.gov/data
  • COVID-19 vaccination is important for all eligible patients and it is important to complete the vaccination series. 
  • Monoclonal antibodies are available for people at high risk of severe disease from COVID-19. 
  • Treatment information can be found at: https://covid19.colorado.gov/for-coloradans/covid-19-treatments.
  • A number of outbreaks have been reported in residential care facilities due to B.1.617.2 (Delta variant), including in facilities with relatively high rates of resident vaccination. CDPHE is now recommending increased testing of unvaccinated staff for facilities located in areas of Colorado where B.1.617.2 is prevalent or rapidly increasing.


This project is funded by a grant from the National Institutes of Health (NIH) and National Center for Advancing Translational Sciences (NCATS) (award number UL1-TR002535-03S3).